Bristol Myers therapy for schizophrenia is safe in late-stage study

Bristol-Myers Squibb (BMS)

hapabapa/iStock Editorial via Getty Images

Bristol Myers Squibb (NYSE:BMY) announced Saturday that its investigational schizophrenia therapy KarXT, acquired as part of its recent acquisition of Karuna Therapeutics, indicated a well-tolerated safety profile in a Phase 3 program.

Citing data from the EMERGENT-4 and EMERGENT-5 studies, the Princeton, New

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *